找回密碼
 To register

QQ登錄

只需一步,快速開(kāi)始

掃一掃,訪問(wèn)微社區(qū)

打印 上一主題 下一主題

Titlebook: Novel Therapeutics for Rare Lymphomas; Christopher Dittus Book 2020 Springer Nature Switzerland AG 2020 lymphoma.novel therapeutics for ra

[復(fù)制鏈接]
查看: 54864|回復(fù): 55
樓主
發(fā)表于 2025-3-21 16:50:19 | 只看該作者 |倒序?yàn)g覽 |閱讀模式
書(shū)目名稱Novel Therapeutics for Rare Lymphomas
編輯Christopher Dittus
視頻videohttp://file.papertrans.cn/669/668467/668467.mp4
概述Discusses the clinical presentation, diagnosis, and treatment approach to rare lymphomas.Focuses on new diagnostic approaches, novel chemotherapy combinations, and new treatment modalities with novel
圖書(shū)封面Titlebook: Novel Therapeutics for Rare Lymphomas;  Christopher Dittus Book 2020 Springer Nature Switzerland AG 2020 lymphoma.novel therapeutics for ra
描述.This comprehensive volume reviews the clinical presentation, diagnosis, and treatment approach to rare lymphomas. There is particular emphasis placed on new diagnostic approaches, novel chemotherapy combinations, and treatment modalities with novel therapeutics. It highlights research advances in a group of diseases that are often overlooked, and serves as a single repository of information on the most recent advances in targeted small molecule inhibitors, monoclonal antibodies, immunotherapy, and CAR-T therapy as they pertain to rare types of lymphoma. Written for practicing oncologists, hematologists, fellows, and residents,?.Novel Therapeutics for Rare Lymphomas.?covers rare subtypes of lymphoma, including indolent and aggressive T-cell lymphomas and B-cell lymphomas..
出版日期Book 2020
關(guān)鍵詞lymphoma; novel therapeutics for rare lymphomas; rare lymphomas; novel therapeutics; t-cell lymphomas; ag
版次1
doihttps://doi.org/10.1007/978-3-030-25610-4
isbn_softcover978-3-030-25612-8
isbn_ebook978-3-030-25610-4
copyrightSpringer Nature Switzerland AG 2020
The information of publication is updating

書(shū)目名稱Novel Therapeutics for Rare Lymphomas影響因子(影響力)




書(shū)目名稱Novel Therapeutics for Rare Lymphomas影響因子(影響力)學(xué)科排名




書(shū)目名稱Novel Therapeutics for Rare Lymphomas網(wǎng)絡(luò)公開(kāi)度




書(shū)目名稱Novel Therapeutics for Rare Lymphomas網(wǎng)絡(luò)公開(kāi)度學(xué)科排名




書(shū)目名稱Novel Therapeutics for Rare Lymphomas被引頻次




書(shū)目名稱Novel Therapeutics for Rare Lymphomas被引頻次學(xué)科排名




書(shū)目名稱Novel Therapeutics for Rare Lymphomas年度引用




書(shū)目名稱Novel Therapeutics for Rare Lymphomas年度引用學(xué)科排名




書(shū)目名稱Novel Therapeutics for Rare Lymphomas讀者反饋




書(shū)目名稱Novel Therapeutics for Rare Lymphomas讀者反饋學(xué)科排名




單選投票, 共有 0 人參與投票
 

0票 0%

Perfect with Aesthetics

 

0票 0%

Better Implies Difficulty

 

0票 0%

Good and Satisfactory

 

0票 0%

Adverse Performance

 

0票 0%

Disdainful Garbage

您所在的用戶組沒(méi)有投票權(quán)限
沙發(fā)
發(fā)表于 2025-3-21 23:17:35 | 只看該作者
板凳
發(fā)表于 2025-3-22 00:27:03 | 只看該作者
Immunotherapy in Hodgkin Lymphoma and Other CD30+ Lymphomas,e Ki-1 antibody binding to Reed-Sternberg cells in Hodgkin lymphoma (Stein et al., Blood 66(4):848–858, 1985). Since it has high expression within Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL), variable expression in other non-Hodgkin lymphoma subgroups, and limited expression in n
地板
發(fā)表于 2025-3-22 05:26:29 | 只看該作者
5#
發(fā)表于 2025-3-22 12:40:50 | 只看該作者
6#
發(fā)表于 2025-3-22 15:01:10 | 只看該作者
7#
發(fā)表于 2025-3-22 19:32:55 | 只看該作者
8#
發(fā)表于 2025-3-23 00:40:29 | 只看該作者
Novel Agents in Primary Central Nervous System Lymphoma,te-based therapies has improved patient outcomes in the first-line setting, the prognosis of relapsed and refractory disease is poor. PCNSL has a unique pathophysiology and gene expression profile, making it more amenable to novel targeted and immunotherapeutic agents. Therapies such as ibrutinib, n
9#
發(fā)表于 2025-3-23 05:16:09 | 只看該作者
10#
發(fā)表于 2025-3-23 09:04:24 | 只看該作者
Extranodal NK/T-Cell Lymphoma,and is characterized by localized lesions involving the nose, nasopharynx, or oropharynx. Extra-nasal disease is less common and generally more aggressive. The immunophenotype of ENKTCL is unique, with most cases expressing NK-cell markers (CD2+, cytoplasmic CD3+, and CD56+). Treatment options for l
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛(ài)論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-12 20:52
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
永胜县| 德昌县| 九台市| 衡水市| 大宁县| 秦皇岛市| 梁山县| 吉林省| 天台县| 璧山县| 潞西市| 陕西省| 崇阳县| 中西区| 慈溪市| 邻水| 金坛市| 金沙县| 浮山县| 康保县| 来安县| 民县| 水富县| 喀什市| 老河口市| 合作市| 辽阳县| 确山县| 商水县| 双桥区| 榕江县| 会同县| 中江县| 万盛区| 无锡市| 霍山县| 新和县| 汕头市| 磴口县| 牟定县| 禹城市|